Trial · NCT00474708
Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
NCT00474708, Phase 4, Completed, Wyeth is now a wholly owned subsidiary of Pfizer; results first posted 2010-04-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients. Trials, record NCT00474708. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00474708
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
- NCT number
- NCT00474708
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,151 participants, actual
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Conditions
- Major Depressive Disorder
- Interventions
- Effexor, SSRI
- First posted
- 2007-05-17
- Last updated
- 2012-03-05
- Results first posted
- 2010-04-30
- Limitations and caveats
- 365 participants were assessed for safety. Certain demographic data (gender and age) is missing for one participant. Thereby resulting in the participant flow reflecting 364 participants.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Achieving Remission | 12 weeks | Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50. |
| Secondary | Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | 12 weeks | Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on a 0 to 2 or 4 scale (0=none/absent and 4=most sever) for a maximum total score of 50. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Achieving Remission | 12 weeks | The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment. | participants | NUMBER |
| SECONDARY | Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | 12 weeks | The analysis population is the per protocol population, consisting of patients who have received at least one dose and have completed the 12 week clinical assessment. A total of 125 (VEN XR=83, SSRI=42) patients had a co-morbid anxiety disorder and 834 (VEN XR=581, SSRI=253) did not. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Achieving Remission | Venlafaxine XR | 554 | participants | ||
| Number of Patients Achieving Remission | SSRI or Conventional Antidepressant Group | 207 | participants | ||
| Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | Venlafaxine XR | Co-morbid anxiety disorder | 60 | participants | |
| Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | SSRI or Conventional Antidepressant Group | Co-morbid anxiety disorder | 23 | participants | |
| Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | Venlafaxine XR | No anxiety disorder | 494 | participants | |
| Number of Patients Achieving Remission (by Co-morbid Anxiety Disorder Status) | SSRI or Conventional Antidepressant Group | No anxiety disorder | 184 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Venlafaxine XR | 791 | |
| Overall Study | STARTED | SSRI or Conventional Antidepressant Group | 367 | |
| Overall Study | COMPLETED | Venlafaxine XR | 734 | |
| Overall Study | COMPLETED | SSRI or Conventional Antidepressant Group | 342 | |
| Overall Study | NOT COMPLETED | Venlafaxine XR | 57 | |
| Overall Study | NOT COMPLETED | SSRI or Conventional Antidepressant Group | 25 |
Source ClinicalTrials.gov
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Venlafaxine XR | 66 | 787 | |
| other | Constipation | Gastrointestinal disorders | SSRI or Conventional Antidepressant Group | 43 | 365 | |
| other | Irritable bowel syndrome | Gastrointestinal disorders | Venlafaxine XR | 1 | 787 | |
| other | Irritable bowel syndrome | Gastrointestinal disorders | SSRI or Conventional Antidepressant Group | 0 | 365 | |
| other | Nausea | Gastrointestinal disorders | Venlafaxine XR | 65 | 787 | |
| other | Nausea | Gastrointestinal disorders | SSRI or Conventional Antidepressant Group | 47 | 365 | |
| other | Diarrhea | Gastrointestinal disorders | Venlafaxine XR | 7 | 787 | |
| other | Diarrhea | Gastrointestinal disorders | SSRI or Conventional Antidepressant Group | 6 | 365 | |
| other | Dry mouth | Gastrointestinal disorders | Venlafaxine XR | 48 | 787 | |
| other | Dry mouth | Gastrointestinal disorders | SSRI or Conventional Antidepressant Group | 24 | 365 |
1 to 10 of 152Source ClinicalTrials.gov
See all 152 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Venlafaxine XR | ||
| Total, all-cause mortality | SSRI or Conventional Antidepressant Group | ||
| Total, other adverse events | Venlafaxine XR | 418 | |
| Total, other adverse events | SSRI or Conventional Antidepressant Group | 236 | |
| Total, serious adverse events | Venlafaxine XR | 3 | |
| Total, serious adverse events | SSRI or Conventional Antidepressant Group | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Venlafaxine XR vs SSRI or Conventional Antidepressant Group: Number of Patients Achieving Remission |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00474708
GET https://conductscience.org/api/trials/v1/NCT00474708/events?page=2